TipRanks
Advertisement
Advertisement
vTv Therapeutics price target raised to $57 from $49 at BTIG
PremiumThe FlyvTv Therapeutics price target raised to $57 from $49 at BTIG
3M ago
vTv Therapeutics initiated with a Buy at Rodman & Renshaw
Premium
The Fly
vTv Therapeutics initiated with a Buy at Rodman & Renshaw
3M ago
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay
Premium
Company Announcements
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay
3M ago
vTv Therapeutics initiated with an Outperform at Evercore ISI
PremiumThe FlyvTv Therapeutics initiated with an Outperform at Evercore ISI
7M ago
vTv Therapeutics price target raised to $55 from $35 at Alliance Global
Premium
The Fly
vTv Therapeutics price target raised to $55 from $35 at Alliance Global
7M ago
Buy Rating on vTv Therapeutics Underpinned by Late-Stage T1D Catalyst, Strengthened Balance Sheet, and Diversified Partnership-Driven Upside
Premium
Ratings
Buy Rating on vTv Therapeutics Underpinned by Late-Stage T1D Catalyst, Strengthened Balance Sheet, and Diversified Partnership-Driven Upside
7M ago
vTv Therapeutics Expands Global HPP737 Rights with Newsoara
PremiumCompany AnnouncementsvTv Therapeutics Expands Global HPP737 Rights with Newsoara
8M ago
vTv Therapeutics expanded its license agreement with Newsoara Biopharma
Premium
The Fly
vTv Therapeutics expanded its license agreement with Newsoara Biopharma
8M ago
vTv Therapeutics price target raised to $49 from $40 at BTIG
Premium
The Fly
vTv Therapeutics price target raised to $49 from $40 at BTIG
8M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―